olmesartan has been researched along with Atheroma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirohata, A; Ito, H; Komatsubara, I; Kusachi, S; Miyoshi, T; Murakami, T; Nakamura, K; Ohe, T; Usui, S; Yamamoto, K | 1 |
| Miura, S; Saku, K | 1 |
1 review(s) available for olmesartan and Atheroma
| Article | Year |
|---|---|
Recent progress in the treatment of cardiovascular disease using olmesartan.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Coronary Artery Disease; Coronary Stenosis; Disease Models, Animal; Humans; Hypertension; Imidazoles; Plaque, Atherosclerotic; Tetrazoles | 2014 |
1 trial(s) available for olmesartan and Atheroma
| Article | Year |
|---|---|
Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial.
Topics: Adiponectin; Aged; Angina, Stable; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Coronary Vessels; Disease Progression; Down-Regulation; Female; Humans; Imidazoles; Inflammation Mediators; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2014 |